Search
for

    Did you mean 5-alpha-reductase 2?
    GlossarySteroid 5 Alpha-Reductase 2

    enzyme converting testosterone to potent androgen dihydrotestosterone (DHT)

    Steroid 5 Alpha-Reductase 2 (also known as 5α-Reductase Type 2 or SRD5A2) is an enzyme that converts testosterone into dihydrotestosterone (DHT), a more potent androgen. This enzyme plays a crucial role in the development of male characteristics and is also implicated in conditions like male pattern baldness and benign prostatic hyperplasia.

    Related Terms

    Learn

    5 / 10 results

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

      learn Saw Palmetto

      a natural and far less effective alternative to Finasteride

      learn Azelaic Acid

      acid used for antimicrobial, anti-inflammatory and anti-androgenic properties

      learn Rosemary

      herb and oil with stimulant, circulatory, anti-inflammatory and antioxidant properties

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community DHT and 5AR respect post, it's importance within the brain

      in Research/Science  111 upvotes 9 months ago
      The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 4 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.